NCI-H2170 Cells

The NCI-H2170 cell line is derived from a human squamous cell carcinoma of the lung. This cell line is widely used in lung cancer research, particularly for studying the molecular mechanisms underlying squamous cell carcinoma, which is a common and aggressive form of lung cancer. NCI-H2170 cells provide a valuable model for investigating the genetic and epigenetic alterations associated with lung cancer, as well as for testing the efficacy of novel therapeutic agents.
NCI-H2170 cells exhibit an epithelial morphology and express markers characteristic of squamous cell carcinoma, including cytokeratins and p63. They harbor genetic mutations typical of lung cancer, such as alterations in the TP53 and CDKN2A genes, which play critical roles in cell cycle regulation and tumor suppression. Researchers use NCI-H2170 cells to explore key signaling pathways involved in lung cancer progression, such as the EGFR, PI3K/Akt, and MAPK pathways. These cells are also employed in drug screening assays to evaluate the effectiveness of chemotherapeutic agents, targeted therapies, and combination treatments. Additionally, NCI-H2170 cells are used to study mechanisms of drug resistance and to develop strategies to overcome it. The relevance of the NCI-H2170 cell line in lung cancer research underscores its importance in advancing our understanding of cancer biology and in the development of new therapeutic approaches for lung cancer patients.